News

21 Jun 2018

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
Read More >>

13 Jun 2018

REPROCELL's footprint extends to serve life sciences in India

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
Read More >>

25 May 2018

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

At REPROCELL, we are continually striving to expand our range of human fresh tissue and 3D models of drug safety and efficacy. REPROCELL hosts the only catalogue of human fresh tissue assays with searchable categories of tissue type, receptor and endpoints across a range of therapeutic areas.
Read More >>

18 May 2018

Factors to consider when planning a iPSC reprogramming project

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.
Read More >>

1 2 3 4 >>

Biopta co-authors research in the European Respiratory Journal

18/11/2015

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.   This abstract describes the biological mechanisms by which a novel chemokine antagonist, AXP1275, impacts lung inflammation through its action at the CCR3-muscarinic M3 receptor heterodimer.  The disease relevance of such biological complexity can only be truly demonstrated in fresh human tissue, in an environment where the receptor and pathway interaction occurs naturally. Click here to access the abstract.

Live chat by BoldChat